Barbara Castelnuovo

Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4⁺Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited Settings

David B. Meya, Yukari C. Manabe, Barbara Castelnuovo et al. · Clinical Infectious Diseases · 2010 · 303 citations · Full text

Public Health, Infectious Diseases, Pharmacoeconomics +17

Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy

Moses R. Kamya, Harriet Mayanja‐Kizza, Andrew Kambugu et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2007 · 210 citations

Life Sciences, Infectious Diseases, Pediatrics +17

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · New England Journal of Medicine · 2021 · 179 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · The Lancet HIV · 2022 · 137 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Cause‐Specific Mortality and the Contribution of Immune Reconstitution Inflammatory Syndrome in the First 3 Years after Antiretroviral Therapy Initiation in an Urban African Cohort

Barbara Castelnuovo, Yukari C. Manabe, Agnes Kiragga et al. · Clinical Infectious Diseases · 2009 · 125 citations

Veterinary Medicine, Immunology, Infectious Diseases +17